AI Summary & Key Takeaways
AI InsightThe screening of nNO with NIOX-MINOmethod provides early diagnose before mucosal biopsy of patients who aresuspected to have PCD and therefore, prevents co-morbidities and prolongssurvival with early treatment.
📌 3 Key Takeaways
Özet
Primary ciliary dyskinesia (PCD) is a rare, inherited disorder characterizedby recurrent respiratory tract infections. The measurement of nasal nitricoxide (nNO) is an important test for the diagnosis of PCD. In this study,we aim to evaluate NIOX-MINOÒ, which is an easily applicable method formeasuring nNO, in the diagnosis of patients with PCD and define diagnosticcut-off levels. Furthermore, determining the normal limits of nNO in healthychildren and investigating nNO levels of children with cystic fibrosis (CF)are the other aims of this study. The children included in this study were5 to 18.5 years old, 46 of them had PCD, 44 had CF and 200 were healthychildren. To our knowledge, this work contains the widest population comparedto previous studies. Subjects receiving steroids or antibiotics or those withany acute respiratory tract infection, asthma or allergic rhinitis were notincluded in the study. Mean nNO levels were found as 10.4, 22.8 and 21.0ppb in PCD, CF and healthy children, respectively. The nNO levels for PCDpatients were found significantly lower than children with CF and the controlgroups (p<0.05). In this study, the diagnostic nNO cut-off level betweenPCD and the other two groups was determined to be <11.5 ppb with %83.6specificity and %67.4 sensitivity. The screening of nNO with NIOX-MINOmethod provides early diagnose before mucosal biopsy of patients who aresuspected to have PCD and therefore, prevents co-morbidities and prolongssurvival with early treatment.